The drug, Journavx by Vertex Pharmaceuticals, blocks pain signals to the brain, making it nonaddictive. The Food and Drug ...

The US Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults ...

Objective: To assess the efficacy, safety and impact on quality of life of tramadol in the treatment of neuropathic pain in patients with cancer. Methods: Patients with similar characteristics ...

Four in every 10 cancer patients treated with chemotherapy develop severe peripheral nerve pain, a new review suggests.

The Company anticipates completing enrollment of the 48-patient trial by the end of 2Q 2025 and releasing top-line data on the Phase 2a trial in 4Q 2025. Results from this trial are anticipated to be ...

Although systematic reviews have outlined the current treatment options for neuropathic pain, subsequent trials have necessitated an update of the NUMBER NEEDED TO TREAT (NNT) values presented in ...

Chemotherapy has been known to cause damage to peripheral nerves, and sometimes the pain is chronic and severe enough that chemotherapy doses are reduced or discontinued. But prior research has not ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...

A recent treatment is offering hope to people suffering from knee pain, especially those over the age of 50. Researchers at MedStar Georgetown University Hospital found that a minimally invasive ...

Vertex Pharma has secured FDA approval for its non-opioid pain drug suzetrigine, becoming the first new class of pain ...